Jennifer Landsberg

List of Publications by Year
in descending order

75 papers	4,015 citations	172457 29 h-index	128289 60 g-index
80 all docs	80 docs citations	80 times ranked	9504 citing authors

#	Article	IF	Citations
1	Itâ€™s Not Always SIAD: Immunotherapy-Triggered Endocrinopathies Enter the Field of Cancer-Related Hyponatremia. Journal of the Endocrine Society, 2022, 6, bvac036.	0.2	4
2	DNA Methylation and mRNA Expression of OX40 (TNFRSF4) and GITR (TNFRSF18, AITR) in Head and Neck Squamous Cell Carcinoma Correlates With HPV Status, Mutational Load, an Interferon-Î³ Signature, Signatures of Immune Infiltrates, and Survival. Journal of Immunotherapy, 2022, 45, 194-206.	2.4	6
3	DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy. Clinical Epigenetics, 2022, 14, 50.	4.1	9
4	CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab). Cancer Immunology, Immunotherapy, 2021, 70, 1781-1788.	4.2	22
5	Treatment Monitoring of Immunotherapy and Targeted Therapy Using ¹⁸F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences. Journal of Nuclear Medicine, 2021, 62, 464-470.	5.0	25
6	Grzybowskiâ€™s Generalized Eruptive Keratoacanthomas in a Patient with Terminal Kidney Diseaseâ€”An Unmet Medical Need Equally Ameliorated by Topical Imiquimod Cream and Lapacho Tea Wraps: A Case Report. Dermatology and Therapy, 2021, 11, 625-638.	3.0	2
7	Prognostic Value of Preoperative Inflammatory Markers in Melanoma Patients with Brain Metastases. Journal of Clinical Medicine, 2021, 10, 634.	2.4	12
8	The Impact of Prolonged Mechanical Ventilation on Overall Survival in Patients With Surgically Treated Brain Metastases. Frontiers in Oncology, 2021, 11, 658949.	2.8	10
9	No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany. BMC Cancer, 2021, 21, 526.	2.6	3
10	Outcome of Elderly Patients With Surgically Treated Brain Metastases. Frontiers in Oncology, 2021, 11, 713965.	2.8	14
11	Combined Assessment of Preoperative Frailty and Sarcopenia Allows the Prediction of Overall Survival in Patients with Lung Cancer (NSCLC) and Surgically Treated Brain Metastasis. Cancers, 2021, 13, 3353.	3.7	18
12	Tumor rejection in Cblb^{â^'/â^'} mice depends on IL-9 and Th9 cells. , 2021, 9, e002889.		11
13	Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer. Journal of Immunotherapy, 2021, 44, 319-324.	2.4	9
14	Intercellular cGAMP transmission induces innate immune activation and tissue inflammation in Trex1 deficiency. IScience, 2021, 24, 102833.	4.1	3
15	Preoperative Metastatic Brain Tumor-Associated Intracerebral Hemorrhage Is Associated With Dismal Prognosis. Frontiers in Oncology, 2021, 11, 699860.	2.8	11
16	Cardiac MRI Depicts Immune Checkpoint Inhibitorâ€“induced Myocarditis: A Prospective Study. Radiology, 2021, 301, 602-609.	7.3	22
17	The Surgical Management of Brain Metastases in Non-Small Cell Lung Cancer (NSCLC): Identification of the Early Laboratory and Clinical Determinants of Survival. Journal of Clinical Medicine, 2021, 10, 4013.	2.4	1
18	Lower Genital Tract Melanomas: Staging, Predictors of Outcome, and New Therapeutic Options. Anticancer Research, 2021, 41, 999-1004.	1.1	5

#	Article	IF	Citations
19	Deep Learning-Based Body Composition Analysis Predicts Outcome in Melanoma Patients Treated with Immune Checkpoint Inhibitors. Diagnostics, 2021, 11, 2314.	2.6	13
20	32. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING AMINO ACID PET IN PATIENTS WITH BRAIN METASTASES. Neuro-Oncology Advances, 2020, 2, ii5-ii6.	0.7	1
21	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ TÂCells. Immunity, 2020, 53, 805-823.e15.	14.3	79
22	Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. Immunity, 2020, 53, 564-580.e9.	14.3	27
23	Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma. EBioMedicine, 2020, 59, 102962.	6.1	31
24	Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome. BMC Cancer, 2020, 20, 355.	2.6	33
25	Comorbidity Burden and Presence of Multiple Intracranial Lesions Are Associated with Adverse Events after Surgical Treatment of Patients with Brain Metastases. Cancers, 2020, 12, 3209.	3.7	21
26	Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report. Frontiers in Oncology, 2020, 10, 611.	2.8	6
27	Clinical Management of Locally Advanced Basal-Cell Carcinomas and Future Therapeutic Directions. Dermatology and Therapy, 2020, 10, 835-846.	3.0	14
28	Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. Clinical Epigenetics, 2020, 12, 94.	4.1	26
29	Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. EBioMedicine, 2020, 52, 102647.	6.1	38
30	Treatment of metastasized melanoma with combined checkpoint inhibition in a patient with highly active multiple sclerosis. Journal of Dermatology, 2020, 47, e184-e185.	1.2	0
31	H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade. Clinical Epigenetics, 2020, 12, 24.	4.1	43
32	Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIBâ€“IV M1c melanoma patients. Cancer Immunology, Immunotherapy, 2020, 69, 759-769.	4.2	20
33	LAG3(LAG-3,CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. , 2020, 8, e000552.		70
34	The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas. Epigenetics, 2020, 15, 1195-1212.	2.7	32
35	DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patientsâ€™ survival, immune cell infiltrates, mutational load, and interferon Î³ signature. EBioMedicine, 2019, 48, 341-352.	6.1	22
36	Joint reconstruction and classification of tumor cells and cell interactions in melanoma tissue sections with synthesized training data. International Journal of Computer Assisted Radiology and Surgery, 2019, 14, 587-599.	2.8	6

#	Article	IF	Citations
37	A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer Center. BMC Cancer, 2019, 19, 1024.	2.6	5
38	Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma. Clinical Epigenetics, 2019, 11, 161.	4.1	49
39	Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study. Clinical Chemistry, 2019, 65, 559-568.	3.2	17
40	Treatment monitoring of immunotherapy and targeted therapy using FET PET in patients with melanoma and lung cancer brain metastases: Initial experiences.. Journal of Clinical Oncology, 2019, 37, e13525-e13525.	1.6	3
41	Detailed analysis of adenosine A2a receptor (ADORA2A) and CD73 (5â€²-nucleotidase,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 OncoImmunology, 2018, 7, e1452579.	4.6	19
42	PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations. EBioMedicine, 2018, 28, 97-104.	6.1	55
43	Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod. Multiple Sclerosis Journal, 2018, 24, 1785-1787.	3.0	6
44	PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas. Oncotarget, 2018, 9, 641-650.	1.8	50
45	RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas. Oncogene, 2018, 37, 6136-6151.	5.9	91
46	CTLA4 methylation predicts response to antiâ€“PD-1 and antiâ€“CTLA-4 immunotherapy in melanoma patients. JCI Insight, 2018, 3, .	5.0	67
47	The epidermal polarity protein Par3 is a nonâ€“cell autonomous suppressor of malignant melanoma. Journal of Experimental Medicine, 2017, 214, 339-358.	8.5	37
48	Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. Clinical Chemistry, 2017, 63, 1288-1296.	3.2	97
49	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity, 2017, 47, 789-802.e9.	14.3	207
50	MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. Cancer Research, 2017, 77, 4697-4709.	0.9	126
51	Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. Cancer Research, 2017, 77, 4684-4696.	0.9	80
52	PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients. Oncotarget, 2017, 8, 41011-41020.	1.8	38
53	Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma. European Journal of Cancer, 2016, 59, 109-112.	2.8	45
54	Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. Neuro-Oncology, 2016, 18, 1462-1464.	1.2	65

#	Article	IF	Citations
55	Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. OncoImmunology, 2016, 5, e1221555.	4.6	43
56	18F-fluoroethyl-L-tyrosine positron emission tomography-guided diagnosis of a malignant intramedullary spinal cord tumor. Oncology Letters, 2016, 12, 4705-4707.	1.8	2
57	The Role of Neutrophilic Inflammation, Angiotropism, and Pericytic Mimicry inÂMelanoma Progression and Metastasis. Journal of Investigative Dermatology, 2016, 136, 372-377.	0.7	25
58	Phorbol ester-induced neutrophilic inflammatory responses selectively promote metastatic spread of melanoma in a TLR4-dependent manner. OncoImmunology, 2016, 5, e1078964.	4.6	13
59	A Preclinical Model of Malignant Peripheral Nerve Sheath Tumor-like Melanoma Is Characterized by Infiltrating Mast Cells. Cancer Research, 2016, 76, 251-263.	0.9	33
60	A key role of GARP in the immune suppressive tumor microenvironment. Oncotarget, 2016, 7, 42996-43009.	1.8	26
61	Genomeâ€wide association study identifies new susceptibility loci for cutaneous lupus erythematosus. Experimental Dermatology, 2015, 24, 510-515.	2.9	66
62	MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nature Communications, 2015, 6, 8755.	12.8	175
63	Immune Cellâ€“Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation. Cancer Discovery, 2014, 4, 674-687.	9.4	226
64	Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature, 2014, 507, 109-113.	27.8	547
65	Phymatous Transformation of Facial Cutaneous Vascular Malformations: Clues to Phyma Pathogenesis. JAMA Dermatology, 2013, 149, 368.	4.1	1
66	Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. OncoImmunology, 2012, 1, 287-357.	4.6	24
67	Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature, 2012, 490, 412-416.	27.8	506
68	Stromal Fibroblastâ€“Specific Expression of ADAM-9 Modulates Proliferation and Apoptosis in Melanoma Cells In Vitro and In Vivo. Journal of Investigative Dermatology, 2012, 132, 2451-2458.	0.7	20
69	Efficacy of Ablative Laser Treatment in Galli-Galli Disease. Archives of Dermatology, 2011, 147, 317.	1.4	15
70	Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly(I:C) leads to myeloid cell maturation and activates NK cells. European Journal of Immunology, 2011, 41, 3028-3039.	2.9	40
71	Neonatal UVB exposure accelerates melanoma growth and enhances distant metastases in Hgfâ€Cdk4^{R24C} C57BL/6 mice. International Journal of Cancer, 2011, 129, 285-294.	5.1	32
72	Tumor-promoting role of signal transducer and activator of transcription (Stat)1 in late-stage melanoma growth. Clinical and Experimental Metastasis, 2010, 27, 133-140.	3.3	40

#	Article	IF	Citations
73	Autochthonous primary and metastatic melanomas in Hgfâ€Cdk4^{R24C} mice evade Tâ€cellâ€mediated immune surveillance. Pigment Cell and Melanoma Research, 2010, 23, 649-660.	3.3	34
74	Complete Regression of Advanced Primary and Metastatic Mouse Melanomas following Combination Chemoimmunotherapy. Cancer Research, 2009, 69, 6265-6274.	0.9	46
75	5â€²-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nature Medicine, 2008, 14, 1256-1263.	30.7	353